Optimizing Patient Outcomes in Chronic Myeloid Leukemia Through the Use of Tyrosine Kinase Inhibitors

Program Description
Chronic myeloid leukemia (CML) is characterized by an increase in immature white blood cells in the blood and bone marrow. Oral tyrosine kinase inhibitors (TKIs) are recommended in the frontline treatment of CML, with a goal of preventing disease progression. Pharmacists play a key role in educating patients receiving TKI therapy, as medication adherence is essential for optimal clinical outcomes. Additionally, pharmacists can assist in preventing and managing drug-associated adverse effects and ensuring drug interactions are avoided. This activity will focus on the role of the pharmacist in using guideline recommendations for treating CML.

Target Audience: Health-system pharmacists, oncology pharmacists, specialty pharmacists
Type of Activity: Application
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:
• Analyze key considerations in frontline treatment selection and monitoring of response in patients with chronic myeloid leukemia (CML)
• Characterize factors affecting clinical decisions in the treatment of CML in the second-line setting and beyond
• Identify common adverse effects and management strategies associated with tyrosine kinase inhibitors used in the management of CML

For questions about this live CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-339-L01-P. The activity is available for CE credit through January 16, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Jordan Baskett, PharmD, BCOP, DPLA, and Brittany Hoffmann-Eubanks, PharmD, MBA, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Kelly McCormick; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.


Activity Disclaimer
Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.